 Multi-centre phase II study low dose intravesical epirubicin treatment superficial bladder cancer Yorkshire Scottish Urological Cancer Research Groups Forty patients multiple recurrent superficial bladder tumours course weekly instillations epirubicin mg ml saline overall response rate side effects minimal